Overview

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Safety, tolerability and pharmacokinetics following single doses
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim